Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$1.92 USD
-0.04 (-2.04%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
AADI 1.92 -0.04(-2.04%)
Will AADI be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AADI
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
Other News for AADI
Aadi Bioscience downgraded to Neutral, shares fall
Aadi Bioscience just downgraded at Piper Sandler, here's why
Hold Rating for Aadi Bioscience Amid Clinical Setbacks and Modest Revenue Projections
Aadi Bioscience cut to hold at Jefferies following Fyarro failure in solid tumors
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates